Table 2.
cHA-C | cHA-E | CVV-M | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Start | End | Peptide | Length | Start | End | Peptide | Length | Start | End | Peptide | Length |
146 | 155 | SSGVSAACSY | 10 | 69 | 76 | LGDCCTAG | 8 | 93 | 98 | WSYIVE | 6 |
267 | 277 | APEYAFALVRG | 11 | 139 | 145 | SWPVHYA | 7 | 150 | 156 | TAACPHA | 7 |
347 | 352 | FGAIAG | 6 | 175 | 184 | YPTLAASYAN | 10 | 264 | 270 | NLVVPRY | 7 |
462 | 469 | LYEKVKLQ * | 8 | 247 | 253 | YWTLLRP | 7 | 289 | 295 | VHDCNTT | 7 |
287 | 297 | AVMCECEAKCQ | 11 | ||||||||
460 | 469 | KKLYEKVKAQ * | 10 |
Note: Here are common or unique epitope-based peptides altered or generated on the cHAs compared to the control, CVV-M; peptides shared by the two cHAs, cHA-C and cHA-E are indicated with *.